Richard Simcock - Concepedia

Author

Richard Simcock

Brighton and Sussex Medical School ORCID

Also Known As

Aumilto Silva, Juliette Wright, Karen McAdam, M Bradburn, R Simcock, R. Simcock, R.A. Simcock, RICHARD SIMCOCK, RS Richard Simcock, Richard A. Simcock

114

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Brighton and Sussex Medical School University Hospitals Sussex NHS Foundation Trust University of Sheffield Royal Derby Hospital Weston Park Cancer Centre

About

Richard Simcock is an author at Brighton and Sussex Medical School specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	331
2	Health Sciences	2	2	174
3	Geriatrics	2	2	28
4	Public Health	1	1	15
5	Head And Neck Surgery	1	1	57

Richard Simcock

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial Helena Earl, Louise Hiller, Anne-Laure Vallier, The Lancet	2019	277
COVID-19: Global radiation oncology’s targeted response for pandemic preparedness Richard Simcock, Toms Vengaloor Thomas, Christopher Estes, Clinical and Translational Radiation Oncology	2020	240
ARIX: A randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer Richard Simcock, Lesley Fallowfield, Kathryn Monson, Annals of Oncology Neck CancerHealth SciencesMedicineRandomised TrialSymptomatic Treatment	2012	104
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Helena Earl, Louise Hiller, Anne-Laure Vallier, Journal of Clinical Oncology Breast OncologyClinical EndpointPopulation Health SciencesDisease-free SurvivalPharmacotherapy	2018	70
Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer Nicolò Matteo Luca Battisti, Malcolm Reed, Esther Herbert, European Journal of Cancer	2020	65
Subcutaneous Trastuzumab (Herceptin&lt;sup&gt;&#174;&lt;/sup&gt;): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer Russell Burcombe, Richard Simcock, Kunal Samanta, Advances in Breast Cancer Research	2013	59
Follow-up and Survivorship in Head and Neck Cancer Richard Simcock, Ricard Simó Clinical Oncology Neck CancerMedicineNasopharyngeal CancerHead And Neck CancerHead And Neck Surgery	2016	57
Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life Lynda Wyld, Malcolm Reed, Jenna Morgan, European Journal of Cancer	2020	52
Bridging the age gap in breast cancer: cluster randomized trial of two decision support interventions for older women with operable breast cancer on quality of life, survival, decision quality, and treatment choices Lynda Wyld, Malcolm Reed, Karen Collins, British journal of surgery	2021	52
Clinically Significant Human Papilloma Virus in Squamous Cell Carcinoma of the Head and Neck in UK Practice Simon Heath, Van C. Willis, K. Allan, Clinical Oncology Cervical CancerSquamous Cell CarcinomaHuman Papillomavirus VaccinesPathologyNeck Pathology	2011	47

Page 1